A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Recruiting

Phase 1

KLN-1010A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Sponsor:

Kelonia Therapeutics, Inc.

Code:

NCT07075185

Conditions

Multiple Myeloma in Relapse

Myeloma Multiple

Multiple Myeloma Progression

Neoplasms by Histologic Type

Neoplasm

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

KLN-1010

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-24. This information was provided to ClinicalTrials.gov by Kelonia Therapeutics, Inc. on 2026-04-16.